DOCSLIB.ORG

Vaginal and Cervical Cancers and Other Abnormalities Associated with Exposure in Utero to Diethylstilbestrol and Related Synthetic Hormones

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vaginal and Cervical Cancers and Other Abnormalities Associated with Exposure in Utero to Diethylstilbestrol and Related Synthetic Hormones [CANCER RESEARCH 37, 1249-1251 , April 1977] Letter to the Editor Vaginal and Cervical Cancers and Other Abnormalities Associated with Exposure in Utero to Diethylstilbestrol and Related Synthetic Hormones Ervin Adam,1 David G. Decker,2 Arthur L. Herbst,3 Kenneth L. NoIler,4 Barbara C. Tilley,5 and Duane E. Townsend6 Professional and Public Relations Committee, Diethylstilbestrol and Adenosis Project, Division of Cancer Control and Rehabilitation, and Office of Cancer Communications, National Cancer Institute, NIH, Department of Health, Education, and Welfare, Bethesda, Maryland 20014 The National Cancer Institute is supporting a study of during pregnancy was loss effective than initially thought. vaginal cancer and other noncancemous genital tract innegu Although its use in pregnancy has now been discontinued, lamitiesin offspring of mothers who received synthetic estro DES remains a useful agent for certain menopausal gens during pregnancy. The study, entitled The DESAD symptoms, certain cases of carcinoma of the breast and Project (DES7 and Adenosis), seeks to provide answers prostate, and a few other clinical problems. A list of DES concerning the risk to exposed offspring born after 1940 of type drugs is found in Table 1. developing cancer on other medically important conditions, In 1971, Dr. Arthur L. Henbst, Dr. Howard Ulfelden, and Dr. including vaginal adenosis and cervical abnormalities. Each David Poskanzer of Massachusetts General Hospital and the of 4 participating institutions8 is identifying 500 or more Harvard Medical School reported a link between maternal subjects with documented in utero exposure. Exposed DES therapy during pregnancy and the later occurrence of daughters of different ages are being examined and fol clear-cell adenocarcinoma of the vagina in female offspring lowod to determine incidence and natural history of vaginal exposed to the drug in utero. This initial report was soon adenosis and other irregularities. confirmed by others. Soon after the discovery of the initial cases, a Registry of Abnormalities Associated with Exposure in Utero to DES Clear-Cell Adonocancinoma of the Genital Tract in Voung DES, a synthetic estrogen-type hormone, was first syn Females was established by Dr. Honbst and Dr. Robert E. thesized in the late 1930's. During the 1940's many physi Scully with support from the National Cancer Institute and cians in the United States and other countries prescribed the American Cancer Society. It now contains varying this substance for pregnant women. Several studios sug amounts of data on almost 300 cases from the United States gested that in complications of pregnancy such as bleed and abroad. The Registry address is MARP, Room 303, 5841 ing, threatened miscarriage, or diabetes, this treatment im MarylandAvenue,Chicago,Ill.60637. proved salvage of the fetus. The patients have ranged in age from 7 to 28 years at the Later studies disclosed that the administration of DES time of diagnosis. Documentation of exposure to DES-type hormones has 1 Present address: Departments of Epidemiology and Obstetrics-Gynecol been established in two-thirds of the fully investigated case ogy, Baylor University, College of Medicine, 1200 M. D. Anderson Street, histories. Of the vaginal adenocancinoma cases, more than Houston, Texas 77025. 80% are known to have been exposed to DES-type hon 2 Present address: Department of Obstetrics-Gynecology, Mayo Clinic, Rochester, Minn. 55901. mones. Because DES-type hormones were not adminis 3 Present address: Department of Obstetrics and Gynecology, University tened to some of the mothers of these cancer patients, of Chicago Medical School, chicago, Ill. 60612. factors other than maternal hormone administration may 4 Present address: Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minn. 55901. also play a role in the etiology of those cancers. S Present address: DESAD Project, Mayo Clinic, Rochester, Minn. 55901. In all cases for which precise treatment dates are availa 6 Present address; Gynecologic Oncology Department, University of ble,thedrug was initiatedbeforethe18thweek of gesta Southern California, School of Medicine, 2025 Zonal Avenue, Los Angeles, Calif. 90033. tion. Dosages and duration of therapy varied widely. How 7 The abbreviation used is: DES, diethylstilbestrol. even, as little as 1.5 mg DES administered daily throughout e The institutions participating in this study, and the principal investiga tons, are: Massachusetts General Hospital, Harvard Medical School, pregnancy was found in 1 case history to be associated with Boston, Mass., Dr. Ann Barnes and Dr. Stanley J. Robboy; University of subsequent cancer in female offspring. Administration of Southern California, Los Angeles, Calif., Dr. Duane E. Townsend; Baylor the drug in varying amounts for a week or mono during the College of Medicine, Houston, Texas; Dr. Raymond H. Kaufman; and Mayo Clinic, Rochester, Minn. , Dr. David G. Decker. 1st trimester also was associated with the subsequent do The Mayo Clinic is coordinating the efforts of the institutions participating velopment of cancer. in the study. Dr. Leonard T. Kunland, Chairman of the Department of Epide Cancers related to DES exposure have not been reported miology and Medical Statistics at Mayo, is directing the study's National Coordinating Center. The Project Director at the National Cancer Institute, in male offspring. Division of Cancer Control and Rehabilitation, is Dr. Mary Ann Sestili, Room Although the exact number of pregnant women treated 6107, Blair Building, 8300 Colesville Road, Silver Spring, Md. 20910. The telephone number is (301)427-7477. with DES on chemically similar compounds during preg Received October 29, 1976; accepted December 15, 1976. nancy is unknown, it has been estimated to be as many as 2 APRIL 1977 1249 Downloaded from cancerres.aacrjournals.org on September 29, 2021. © 1977 American Association for Cancer Research. National Cancer Institute Table 1 nal clear-cell adenocarcinomas, whether or not a history of DES-type drugs that may have been prescribed to pregnant women DES-type drug exposure in utero is confirmed. Vaginal ad Nonsteroidalestrogens enosis is manein normal (unexposod) young women. Benzestrol Mikarol forti The results of examinations of females exposed in utero Chlorotnianisene Milestrol to DES-type drugs have been reported in several studies. Comestrol Monomestrol More than one-third of those who were exposed in the first 4 CymenA Neo-OestranolI CyrenB Neo-OestmanolII months of gestation have vaginal adenosis, and more than Delvinal Nulabort two-thirds have cervical ectropion. Other abnormalities DES Oestrogenme seen in these examinations, such as transverse vaginal and DesPlex Oestmomenin cervical ridges, also may be associated with intrauterine Diestryl Oestromon Dibestil Orestol exposure to DES-type drugs. These are described by a Dienestrol PabestrolD. variety of names: hood, pseudopolyp, rim, collar, and Dienoestrol Palestrol cockscomb cervix. Diethylstilbestroldipalmitate Restrol Diethylstilbestmoldiphosphate Stil-Rol Management of Females Exposed to DES-type Drugs Diethylstilbestroldipropionate Stilbal Diethylstilbenediol Stilbestrol Digestil Stilbestronate All asymptomatic girls who wore exposed in utero should Domestrol Stilbetin receive a thorough pelvic examination at menarche on if Estilben Stilbinol they have reached 14 years of age. Vounger girls should be Estrobene Stilboestroform EstrobeneDP. Stilboestrol examined if they develop abnormal bleeding or discharge. Estrosyn Stilboestrol DP. Whenever prenatal exposure is probable and theme are Fonatol Stilestrate symptoms of discharge, further investigation is imperative, Gynben Stilpalmitate regardless of the patient's age. This investigation should Gyneben Stilphostrol not be concluded until it is certain that no lesion is present. Hexestrol Stilronate Hexoestrol Stilrone Before the examination is undertaken, the entire proce Hi-Bestrol Stils dune should be thoroughly discussed with the patient (and Menocnin Synestrmn hen mother on fathomif she is a minor). Meprane Synestrol The examination should include inspection and palpa Mestilbol Synthoestrin Methallenestril Tace tion, Papanicolaou smear (cervix and vagina), and an iodine Micmoest Vallestril staining test of the entire cervix and vagina. Abnormal Mikarol Willestrol areas, including those that do not stain with iodine, should be biopsied. This procedure can be performed in the physi Nonsteroidal estrogen-androgen com binations cian's office with small biopsy instruments and without Amperone Teserene significant discomfort. Di-Erone Tylandril Fomtheveryyoung pationtwho hassymptomsthat require Estan Tylosterone investigation, anesthesia may occasionally be required be Metystil fore an examination. A small spoculum permits adequate Nonsteroidal estrogen-progesterone combination visualization of the vagina without undue discomfort in Progravidium younger patients. With asymptomatic females, if adequate examination is Vaginal cream-suppositorieswith non not possible at the initial visit, vaginal tampons should be steroidalestrogens used for a few months to allow an adequato oxamination AVC cream with Dienestrol Dienestrolcream later without discomfort. Colposcopy is a useful adjunct to this examination, but it is not ossontial. Utilizing its low power magnification to examine the vagina and cervix, the million. The risk of developing adenocarcinoma in exposed physician can identify areas of glandular tissue (adenosis) females under 30 appears to be
Load more

Recommended publications
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Ovarian Insufficiency and CTNNB1 Mutations Drive Malignant Transformation of Endometrial Hyperplasia with Altered PTEN/PI3K Activities
    Ovarian insufficiency and CTNNB1 mutations drive malignant transformation of endometrial hyperplasia with altered PTEN/PI3K activities Jumpei Terakawaa,b,1,2, Vanida Ann Sernaa,b,1, Makoto Mark Taketoc, Takiko Daikokud, Adrian A. Suarezb,e, and Takeshi Kuritaa,b,3 aDepartment of Cancer Biology and Genetics, Ohio State University, Columbus, OH 43210; bThe Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210; cDivision of Experimental Therapeutics, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, 606-8506 Kyoto, Japan; dDivision of Transgenic Animal Science, Advanced Science Research Center, Kanazawa University, 920-8640 Kanazawa, Japan; and eDepartment of Pathology, Ohio State University, Columbus, OH 43210 Edited by Patricia K. Donahoe, Pediatric Surgical Research Laboratories, Massachusetts General Hospital, Department of Surgery, Harvard Medical School, Boston, MA, and approved January 23, 2019 (received for review August 28, 2018) Endometrioid endometrial carcinomas (EECs) carry multiple driver PI3K (5). However, PTEN and PI3K (PIK3CA or PIK3R1)mu- mutations even when they are low grade. However, the biological tations co-occurred in 67% (59/88) of CL-EECs. This observation significance of these concurrent mutations is unknown. We explored questions the widely accepted concept that the loss of PTEN and the interactions among three signature EEC mutations: loss-of- activation of PI3K have synonymous effects on cellular physiology, as function (LOF) mutations in PTEN, gain-of-function (GOF) mutations they catalyze opposite reactions: PI3K converts phosphatidylinositol of phosphoinositide 3-kinase (PI3K), and CTNNB1 exon 3 mutations, (4,5)-biphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate utilizing in vivo mutagenesis of the mouse uterine epithelium.
    [Show full text]
  • Vaginal Cancer, Risk Factors, and Prevention Risk Factors for Vaginal
    cancer.org | 1.800.227.2345 Vaginal Cancer, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for vaginal cancer. ● Risk Factors for Vaginal Cancer ● What Causes Vaginal Cancer? Prevention There's no way to completely prevent cancer. But there are things you can do that might help lower your risk. Learn more here. ● Can Vaginal Cancer Be Prevented? Risk Factors for Vaginal Cancer A risk factor is anything that affects your chance of getting a disease such as cancer. Different cancers have different risk factors. Some risk factors, like smoking, can be changed. Others, like a person’s age or family history, can’t be changed. But having a risk factor, or even many, does not mean that you will get the disease. And 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 some people who get the disease may not have any known risk factors. Scientists have found that certain risk factors make a woman more likely to develop vaginal cancer. But many women with vaginal cancer don’t have any clear risk factors. And even if a woman with vaginal cancer has one or more risk factors, it’s impossible to know for sure how much that risk factor contributed to causing the cancer. Age Squamous cell cancer of the vagina occurs mainly in older women. It can happen at any age, but few cases are found in women younger than 40. Almost half of cases occur in women who are 70 years old or older.
    [Show full text]
  • Pharmacology/Therapeutics II Block III Lectures 2013-14
    Pharmacology/Therapeutics II Block III Lectures 2013‐14 66. Hypothalamic/pituitary Hormones ‐ Rana 67. Estrogens and Progesterone I ‐ Rana 68. Estrogens and Progesterone II ‐ Rana 69. Androgens ‐ Rana 70. Thyroid/Anti‐Thyroid Drugs – Patel 71. Calcium Metabolism – Patel 72. Adrenocorticosterioids and Antagonists – Clipstone 73. Diabetes Drugs I – Clipstone 74. Diabetes Drugs II ‐ Clipstone Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones Date: Thursday, March 20, 2014-8:30 AM Reading Assignment: Katzung, Chapter 37 Key Concepts and Learning Objectives To review the physiology of neuroendocrine regulation To discuss the use neuroendocrine agents for the treatment of representative neuroendocrine disorders: growth hormone deficiency/excess, infertility, hyperprolactinemia Drugs discussed Growth Hormone Deficiency: . Recombinant hGH . Synthetic GHRH, Recombinant IGF-1 Growth Hormone Excess: . Somatostatin analogue . GH receptor antagonist . Dopamine receptor agonist Infertility and other endocrine related disorders: . Human menopausal and recombinant gonadotropins . GnRH agonists as activators . GnRH agonists as inhibitors . GnRH receptor antagonists Hyperprolactinemia: . Dopamine receptor agonists 1 Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. 1. Overview of Neuroendocrine Systems The neuroendocrine
    [Show full text]
  • Sex Determination and Differentiation
    The new england journal of medicine review article mechanisms of disease Sex Determination and Differentiation David T. MacLaughlin, Ph.D., and Patricia K. Donahoe, M.D. ex determination, which depends on the sex-chromosome com- From the Pediatric Surgical Research Lab- plement of the embryo, is established by multiple molecular events that direct the oratories and the Pediatric Surgical Servic- s es, Massachusetts General Hospital and development of germ cells, their migration to the urogenital ridge, and the forma- Harvard Medical School, Boston. Address tion of either a testis, in the presence of the Y chromosome (46,XY), or an ovary in the reprint requests to Dr. MacLaughlin or Dr. absence of the Y chromosome and the presence of a second X chromosome (46,XX). Donahoe at the Pediatric Surgical Research Laboratories, Massachusetts General Hos- Sex determination sets the stage for sex differentiation, the sex-specific response of tis- pital, Boston, MA 02114, or at maclaughlin@ sues to hormones produced by the gonads after they have differentiated in a male or fe- helix.mgh.harvard.edu or donahoe.patricia male pattern. A number of genes have been discovered that contribute both early and late @mgh.harvard.edu. to the process of sex determination and differentiation. In many cases our knowledge has N Engl J Med 2004;350:367-78. derived from studies of either spontaneous or engineered mouse mutations that cause Copyright © 2004 Massachusetts Medical Society. phenotypes similar to those in humans. We will examine how mutations in these genes cause important clinical syndromes (Table 1 and Fig. 1) and discuss clinical entities that continue to elude classification at the molecular level.
    [Show full text]
  • A Pharmaceutical Product for Hormone Replacement Therapy Comprising Tibolone Or a Derivative Thereof and Estradiol Or a Derivative Thereof
    Europäisches Patentamt *EP001522306A1* (19) European Patent Office Office européen des brevets (11) EP 1 522 306 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: A61K 31/567, A61K 31/565, 13.04.2005 Bulletin 2005/15 A61P 15/12 (21) Application number: 03103726.0 (22) Date of filing: 08.10.2003 (84) Designated Contracting States: • Perez, Francisco AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 08970 Sant Joan Despi (Barcelona) (ES) HU IE IT LI LU MC NL PT RO SE SI SK TR • Banado M., Carlos Designated Extension States: 28033 Madrid (ES) AL LT LV MK (74) Representative: Markvardsen, Peter et al (71) Applicant: Liconsa, Liberacion Controlada de Markvardsen Patents, Sustancias Activas, S.A. Patent Department, 08028 Barcelona (ES) P.O. Box 114, Favrholmvaenget 40 (72) Inventors: 3400 Hilleroed (DK) • Palacios, Santiago 28001 Madrid (ES) (54) A pharmaceutical product for hormone replacement therapy comprising tibolone or a derivative thereof and estradiol or a derivative thereof (57) A pharmaceutical product comprising an effec- arate or sequential use in a method for hormone re- tive amount of tibolone or derivative thereof, an effective placement therapy or prevention of hypoestrogenism amount of estradiol or derivative thereof and a pharma- associated clinical symptoms in a human person, in par- ceutically acceptable carrier, wherein the product is pro- ticular wherein the human is a postmenopausal woman. vided as a combined preparation for simultaneous, sep- EP 1 522 306 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 1 522 306 A1 2 Description [0008] The review article of Journal of Steroid Bio- chemistry and Molecular Biology (2001), 76(1-5), FIELD OF THE INVENTION: 231-238 provides a review of some of these compara- tive studies.
    [Show full text]
  • Case Report a Report of Two Cases of Age-Related Changes in Cervical Morphology in Postmenopausal Women with Vaginal Adenosis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Crossref Hindawi Case Reports in Obstetrics and Gynecology Volume 2017, Article ID 9523853, 4 pages https://doi.org/10.1155/2017/9523853 Case Report A Report of Two Cases of Age-Related Changes in Cervical Morphology in Postmenopausal Women with Vaginal Adenosis Marguerite B. Vigliani Alpert Medical School at Brown University, Providence, RI, USA Correspondence should be addressed to Marguerite B. Vigliani; [email protected] Received 28 October 2016; Accepted 18 December 2016; Published 2 January 2017 Academic Editor: John P. Geisler Copyright © 2017 Marguerite B. Vigliani. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This paper presents two cases of women who had extensive vaginal adenosis from prenatal DES exposure, extending almost halfway down the vaginal canal. Both women were followed for decades with annual exams and Pap smears until after menopause. Clinical examination in both cases initially showed an absent pars vaginalis of the cervix, vaginal adenosis, and shallowness of the fornices. Several decades of annual exams showed these stigmata of DES exposure gradually disappear as the upper vagina progressively contracted. After menopause the upper vagina in both cases transformed into what appeared to be a normal cervix with all adenosis involuted into a normal endocervical canal. A timeline was created to show the morphological changes that were observed over time. This timeline illustrates how severe vaginal stenosis above the level of the squamocolumnar junction developed in middle age and was followed in the postmenopause by fusion of the upper vaginal walls in the midline resulting in the appearance of a normal, but prolapsed, cervix.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0304998 A1 Sem (43) Pub
    US 20100304998A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0304998 A1 Sem (43) Pub. Date: Dec. 2, 2010 (54) CHEMICAL PROTEOMIC ASSAY FOR Related U.S. Application Data OPTIMIZING DRUG BINDING TO TARGET (60) Provisional application No. 61/217,585, filed on Jun. PROTEINS 2, 2009. (75) Inventor: Daniel S. Sem, New Berlin, WI Publication Classification (US) (51) Int. C. GOIN 33/545 (2006.01) Correspondence Address: GOIN 27/26 (2006.01) ANDRUS, SCEALES, STARKE & SAWALL, LLP C40B 30/04 (2006.01) 100 EAST WISCONSINAVENUE, SUITE 1100 (52) U.S. Cl. ............... 506/9: 436/531; 204/456; 435/7.1 MILWAUKEE, WI 53202 (US) (57) ABSTRACT (73) Assignee: MARQUETTE UNIVERSITY, Disclosed herein are methods related to drug development. Milwaukee, WI (US) The methods typically include steps whereby an existing drug is modified to obtain a derivative form or whereby an analog (21) Appl. No.: 12/792,398 of an existing drug is identified in order to obtain a new therapeutic agent that preferably has a higher efficacy and (22) Filed: Jun. 2, 2010 fewer side effects than the existing drug. Patent Application Publication Dec. 2, 2010 Sheet 1 of 22 US 2010/0304998 A1 augavpop, Patent Application Publication Dec. 2, 2010 Sheet 2 of 22 US 2010/0304998 A1 g Patent Application Publication Dec. 2, 2010 Sheet 3 of 22 US 2010/0304998 A1 Patent Application Publication Dec. 2, 2010 Sheet 4 of 22 US 2010/0304998 A1 tg & Patent Application Publication Dec. 2, 2010 Sheet 5 of 22 US 2010/0304998 A1 Patent Application Publication Dec.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    THE ORGANIC CHEMISTRY OF DRUG SYNTHESIS VOLUME 3 DANIEL LEDNICER Analytical Bio-Chemistry Laboratories, Inc. Columbia, Missouri LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS New York • Chlchester • Brisbane * Toronto • Singapore Copyright © 1984 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging In Publication Data: (Revised for volume 3) Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." Includes bibliographical references and index. 1. Chemistry, Pharmaceutical. 2. Drugs. 3. Chemistry, Organic—Synthesis. I. Mitscher, Lester A., joint author. II. Title. [DNLM 1. Chemistry, Organic. 2. Chemistry, Pharmaceutical. 3. Drugs—Chemical synthesis. QV 744 L473o 1977] RS403.L38 615M9 76-28387 ISBN 0-471-09250-9 (v. 3) Printed in the United States of America 10 907654321 With great pleasure we dedicate this book, too, to our wives, Beryle and Betty. The great tragedy of Science is the slaying of a beautiful hypothesis by an ugly fact. Thomas H. Huxley, "Biogenesis and Abiogenisis" Preface Ihe first volume in this series represented the launching of a trial balloon on the part of the authors. In the first place, wo were not entirely convinced that contemporary medicinal (hemistry could in fact be organized coherently on the basis of organic chemistry.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Lesbians' Access to and Quality of Healthcare
    HETROSEXISM IN MEDICINE: LESBIANS’ ACCESS TO AND QUALITY OF HEALTHCARE Hannah Banfield Thesis submitted in partial fulfillment of the requirements for the Degree of Bachelor of Arts with Honours in Sociology Acadia University April, 2010 © Copyright by Hannah Banfield, 2010 This thesis by Hannah Banfield is accepted in its present form by the Department of Sociology as satisfying the thesis requirements for the degree of Bachelor of Arts with Honours Approved by the Thesis Supervisor __________________________ ____________________ Dr. Zelda Abramson Date Approved by the Head of the Department __________________________ ____________________ Dr. Jim Sacouman Date Approved by the Honours Committee __________________________ ____________________ Dr. Sonja Hewitt Date ii I, Hannah Banfield, grant permission to the University Librarian at Acadia University to reproduce, loan, or distribute copies of my thesis in microform, paper or electronic formats on a non-profit basis. I however, retain the copyright in my thesis. _________________________________ Signature of Author _________________________________ Date iii ACKNOWLEDGEMENTS There are several people without whom this work would not have been possible. Foremost, I would like to thank the women who consented to be interviewed, giving their time and sharing their experiences. Their collective efforts are the heart of this project. I am especially grateful to my supervisor, Dr. Zelda Abramson, who recognized a potential in me of which I was not aware. Zelda, your guidance and support have been invaluable and your passion infectious. I would like to express my sincere gratitude to Karen Turner, the department‟s administrative assistant. Karen, you go above and beyond in every way. Your insight has been so valuable, but your friendship is priceless.
    [Show full text]